These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 14652793)
61. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Smith KJ; McDonald WI Philos Trans R Soc Lond B Biol Sci; 1999 Oct; 354(1390):1649-73. PubMed ID: 10603618 [TBL] [Abstract][Full Text] [Related]
63. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Friese MA; Schattling B; Fugger L Nat Rev Neurol; 2014 Apr; 10(4):225-38. PubMed ID: 24638138 [TBL] [Abstract][Full Text] [Related]
64. We should focus more on finding therapeutic targets for the non-inflammatory damage in MS - Yes. Garber JY; Barnett MH Mult Scler; 2018 Sep; 24(10):1272-1274. PubMed ID: 29656673 [No Abstract] [Full Text] [Related]
65. We should focus more on finding therapeutic targets for the non-inflammatory damage in MS - Commentary. Al Sultan AS; Stys PK Mult Scler; 2018 Sep; 24(10):1276-1277. PubMed ID: 29656697 [No Abstract] [Full Text] [Related]
66. We should focus more on finding therapeutic targets for the non-inflammatory damage in MS - No. 't Hart BA; Weissert R Mult Scler; 2018 Sep; 24(10):1274-1276. PubMed ID: 29656691 [No Abstract] [Full Text] [Related]
69. Editorial comments: Is multiple sclerosis a neurodegenerative or inflammatory disease? Korczyn AD J Neural Transm (Vienna); 2013 Oct; 120(10):1457. PubMed ID: 24057506 [No Abstract] [Full Text] [Related]
70. Chemotactic signaling and beyond: link between interleukin-16 and axonal degeneration in multiple sclerosis. Skundric DS Neural Regen Res; 2015 Nov; 10(11):1761-3. PubMed ID: 26807108 [No Abstract] [Full Text] [Related]
71. Mechanisms of neuronal damage in multiple sclerosis and its animal models: role of calcium pumps and exchangers. Kurnellas MP; Donahue KC; Elkabes S Biochem Soc Trans; 2007 Nov; 35(Pt 5):923-6. PubMed ID: 17956247 [TBL] [Abstract][Full Text] [Related]
73. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053 [TBL] [Abstract][Full Text] [Related]
74. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade. Van der Walt A; Butzkueven H; Kolbe S; Marriott M; Alexandrou E; Gresle M; Egan G; Kilpatrick T Pharmacol Ther; 2010 Apr; 126(1):82-93. PubMed ID: 20122960 [TBL] [Abstract][Full Text] [Related]
75. From inflammation to degeneration: the lessons of clinical trials. Comi G Neurol Sci; 2003 Dec; 24 Suppl 5():S295-7. PubMed ID: 14652793 [TBL] [Abstract][Full Text] [Related]
76. Inflammation and degeneration in multiple sclerosis. Brück W; Stadelmann C Neurol Sci; 2003 Dec; 24 Suppl 5():S265-7. PubMed ID: 14652785 [TBL] [Abstract][Full Text] [Related]
77. Protecting axons in multiple sclerosis. Wilkins A; Scolding N Mult Scler; 2008 Sep; 14(8):1013-25. PubMed ID: 18632772 [TBL] [Abstract][Full Text] [Related]